AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12709724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 400 mg twice daily for 14 days
Number of subjects: 30
Study 10608477 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 25
Study 10608477 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily
Number of subjects: 25
Study 7726133 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephelometric method
Number of subjects: 330
Study 7726133 — intervention group
Group type: COMPARATOR
Intervention: Hemolytic inhibition assay
Number of subjects: 330
Study 1971597 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0
Study 1971597 — intervention group
Group type: COMPARATOR
Intervention: Covered corridor walking test (Control)
Number of subjects: 0
Study 7402804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits starting prenatally (Group A)
Number of subjects: 115
Study 7402804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits starting at six weeks postpartum (Group B)
Number of subjects: 115
Study 7402804 — intervention group
Group type: COMPARATOR
Intervention: No home visits (Group C)
Number of subjects: 115
Study 30922285 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention combining participatory ergonomics, case management, and health promotion.
Number of subjects: 0
Study 30922285 — intervention group
Group type: COMPARATOR
Intervention: Occupational health care as usual (Control group).
Number of subjects: 0
Study 30922285 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention.
Number of subjects: 0
Study 28818733 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood trauma exposure
Number of subjects: 56
Study 28818733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 56
Study 26790793 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Tranexamic Acid (TXA) 15 mg/kg before and 10 mg/kg 1 hour after surgery
Number of subjects: 90
Study 26790793 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (TXA) 2 g
Number of subjects: 90
Study 26790793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA applied)
Number of subjects: 90
Study 23168135 — intervention group
Group type: EXPERIMENTAL
Intervention: Backfill with hydroxyapatite-calcium triphosphate (HCT) biphasic compound
Number of subjects: 40
Study 23168135 — intervention group
Group type: COMPARATOR
Intervention: No backfill (Control)
Number of subjects: 40
Study 22073137 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc delivered by village health workers (VHWs)
Number of subjects: 12
Study 22073137 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc delivered by outpatient department (OPD) nurses
Number of subjects: 12
Study 22073137 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc delivered by EPI nurses
Number of subjects: 12
Study 22073137 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc delivered by VHWs
Number of subjects: 12
Study 22073137 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc delivered by facility-based nurses
Number of subjects: 12
Study 22073137 — intervention group
Group type: COMPARATOR
Intervention: VHWs
Number of subjects: 12
Study 19926574 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV L1+ cases
Number of subjects: 187
Study 19926574 — intervention group
Group type: COMPARATOR
Intervention: HPV L1- cases
Number of subjects: 187
Study 16990664 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65 antibody response
Number of subjects: 36
Study 12809069 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral piracetam treatment
Number of subjects: 193
Study 12809069 — intervention group
Group type: COMPARATOR
Intervention: Traditional meprobamat therapy
Number of subjects: 193
Study 11014392 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine patch coupled with a controlled heat-aided drug delivery (CHADD) patch
Number of subjects: 12
Study 11014392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9483483 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate therapy (Group I)
Number of subjects: 50
Study 9483483 — intervention group
Group type: COMPARATOR
Intervention: No magnesium treatment (Group II)
Number of subjects: 50
Study 8620676 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 200 to 800mg
Number of subjects: 16
Study 8620676 — intervention group
Group type: EXPERIMENTAL
Intervention: N-dehydroxylated metabolite of zileuton
Number of subjects: 16
Study 8620676 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucuronide metabolites of zileuton
Number of subjects: 16
Study 2751854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (H2 antagonist)
Number of subjects: 0
Study 326482 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (dose up to 800 mg daily)
Number of subjects: 53
Study 326482 — intervention group
Group type: COMPARATOR
Intervention: Practolol (in controlled double-blind trial with placebo)
Number of subjects: 53
Study 326482 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (in exercise tolerance tests)
Number of subjects: 53
Study 326482 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term administration of practolol
Number of subjects: 53
Study 31860328 — intervention group
Group type: COMPARATOR
Intervention: Standard 6‐month course of tuberculosis treatment (180 days), dosed every other day (90 doses)
Number of subjects: 780
Study 31775800 — intervention group
Group type: COMPARATOR
Intervention: Dietary weight loss intervention
Number of subjects: 439
Study 31775800 — intervention group
Group type: COMPARATOR
Intervention: Diet + exercise intervention
Number of subjects: 439
Study 31775800 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 439
Study 31775800 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (no lifestyle change)
Number of subjects: 439
Study 30380221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg · kg⁻¹ loading dose for 10 min, followed by 0.7 μg · kg⁻¹ · hr⁻¹ maintenance)
Number of subjects: 37
Study 30380221 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 μg · kg⁻¹ loading dose, followed by 1-2 μg · kg⁻¹ · hr⁻¹ maintenance)
Number of subjects: 37
Study 25882743 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylethanol (PEth)
Number of subjects: 44
Study 25882743 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-deficient transferrin (CDT)
Number of subjects: 44
Study 25882743 — intervention group
Group type: COMPARATOR
Intervention: Traditional alcohol markers (including MCV, GGT, AST, ALT)
Number of subjects: 44
Study 24728035 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI followed by docetaxel and cisplatin
Number of subjects: 1100
Study 24728035 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 1100
Study 21643812 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (intensive lipid-lowering therapy for 6 months)
Number of subjects: 76
Study 21643812 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (moderate lipid-lowering therapy for 6 months)
Number of subjects: 76
Study 19026406 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement for tic absence on a 10‐s fixed interval schedule in the presence of a purple light
Number of subjects: 10
Study 19026406 — intervention group
Group type: COMPARATOR
Intervention: Instructions to suppress tics in the presence of an orange light without reinforcement
Number of subjects: 10
Study 19026406 — intervention group
Group type: COMPARATOR
Intervention: No instructions to suppress tics in the presence of two non-illuminated lights
Number of subjects: 10
Study 19026406 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of purple light
Number of subjects: 10
Study 19026406 — intervention group
Group type: COMPARATOR
Intervention: Presence of orange light
Number of subjects: 10
Study 19026406 — intervention group
Group type: COMPARATOR
Intervention: Neither light illuminated
Number of subjects: 10
Study 17301737 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2.5 mg tibolone
Number of subjects: 23
Study 17301737 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of tibolone (placebo, 0.3, 0.625, 1.25, or 2.5 mg/day for 26 cycles of 28 days)
Number of subjects: 23
Study 15333300 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused preschool child obesity intervention
Number of subjects: 0
Study 11304601 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream 1.5 g/10 cm2 applied for 2 to 5 hours
Number of subjects: 403
Study 11304601 — intervention group
Group type: COMPARATOR
Intervention: Infiltrated lidocaine
Number of subjects: 403
Study 11304601 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream 3 g/10 cm2
Number of subjects: 403
Study 11304601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (EMLA cream)
Number of subjects: 403
Study 9356540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program designed to lower plasma cholesterol through dietary modifications
Number of subjects: 125
Study 9356540 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with a stronger family history of CAD)
Number of subjects: 125
Study 9356540 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo E phenotype and Lp(a) measurements
Number of subjects: 125
Study 1279611 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120-mg thrice daily)
Number of subjects: 8
Study 1279611 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60-mg thrice daily)
Number of subjects: 8
Study 1279611 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 8
Study 1279611 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8
Study 1279611 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 8
Study 2936269 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg
Number of subjects: 0
Study 2936269 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum 0.4 mg/kg
Number of subjects: 0
Study 2936269 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine 0.008 mg/kg
Number of subjects: 0
Study 30336685 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation of 2000 IU/d
Number of subjects: 45
Study 30336685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29396643 — intervention group
Group type: EXPERIMENTAL
Intervention: C31G (group A)
Number of subjects: 42
Study 29396643 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free CHX 0.12% (group B)
Number of subjects: 42
Study 29396643 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based CHX 0.12% (group C)
Number of subjects: 42
Study 26706023 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat-based diet
Number of subjects: 54
Study 26706023 — intervention group
Group type: COMPARATOR
Intervention: Refined cereal products (Control)
Number of subjects: 54
Study 26706023 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat-based diet (with high fasting propionate changes)
Number of subjects: 54
Study 25179672 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (WBI) for concerned partners (CPs) of service members with alcohol misuse; 4 sessions, adapted from the Community Reinforcement and Family Training (CRAFT) intervention.
Number of subjects: 100
Study 25179672 — intervention group
Group type: COMPARATOR
Intervention: Delayed-web based intervention (delayed-WBI) for concerned partners (CPs) of service members with alcohol misuse.
Number of subjects: 100
Study 22395587 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% and 10% topical sulfur ointment applied for a single day (24 hours)
Number of subjects: 97
Study 22395587 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% and 10% topical sulfur ointment applied for three successive nights
Number of subjects: 97
Study 22395587 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% and 10% topical sulfur ointment applied for three successive days
Number of subjects: 97
Study 22395587 — intervention group
Group type: COMPARATOR
Intervention: Comparison of three groups (single day, three nights, three days)
Number of subjects: 97
Study 22395587 — intervention group
Group type: COMPARATOR
Intervention: Group A (single day)
Number of subjects: 97
Study 22395587 — intervention group
Group type: COMPARATOR
Intervention: Group B (three nights)
Number of subjects: 97
Study 22395587 — intervention group
Group type: COMPARATOR
Intervention: Group C (three days)
Number of subjects: 97
Study 22395587 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of 8% and 10% sulfur
Number of subjects: 97
Study 19965971 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of heparin and aspirin
Number of subjects: 334
Study 19965971 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 334
Study 16735113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 micro g bd
Number of subjects: 233
Study 16735113 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) 200 micro g bd
Number of subjects: 233
Study 16735113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 233
Study 16735113 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD)
Number of subjects: 233
Study 16735113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FP and BUD
Number of subjects: 233
Study 15952261 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive interference from previous lists in a speeded-recognition task
Number of subjects: 0
Study 12505249 — intervention group
Group type: EXPERIMENTAL
Intervention: High-vegetable, low-fat diet intervention with intensive telephone counseling, cooking classes, and print materials to encourage dietary changes.
Number of subjects: 3088
Study 12505249 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control group).
Number of subjects: 3088
Study 9863300 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-interferon (subcutaneous or intramuscular administration)
Number of subjects: 0
Study 9863300 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0
Study 8705152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerin 0.3 mg
Number of subjects: 100
Study 8705152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerin 0.5 mg
Number of subjects: 100
Study 8705152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerin 0.75 mg
Number of subjects: 100
Study 8705152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerin 1.0 mg
Number of subjects: 100
Study 8705152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 2205610 — intervention group
Group type: COMPARATOR
Intervention: Jobst pressure garments
Number of subjects: 110
Study 2205610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubigrip pressure garments
Number of subjects: 110
Study 7033016 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone 100 mg daily
Number of subjects: 6
Study 7033016 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid 1000 mg daily
Number of subjects: 6
Study 7033016 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 300 mg daily
Number of subjects: 6
Study 7033016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30794093 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving-based interactive video games (DBIVG)
Number of subjects: 24
Study 30794093 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT) + Driving-based interactive video games (DBIVG)
Number of subjects: 24
Study 30794093 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT) + Treadmill walking training
Number of subjects: 24
Study 31658725 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg iron daily
Number of subjects: 791
Study 31658725 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg iron daily
Number of subjects: 791
Study 31658725 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg iron daily
Number of subjects: 791
Study 29202732 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted kyphosis-specific exercise and posture training program, delivered by a physical therapist, 1 hour, twice a week for 3 months.
Number of subjects: 112
Study 29202732 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control for 3 months before receiving the delayed intervention.
Number of subjects: 112
Study 29202732 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted kyphosis-specific exercise and posture training program.
Number of subjects: 112
Study 25324445 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol and ondansetron
Number of subjects: 32
Study 25324445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23887167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hecolin (recombinant hepatitis E vaccine)
Number of subjects: 14065
Study 23887167 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hepatitis B vaccine)
Number of subjects: 14065
Study 21538380 — intervention group
Group type: EXPERIMENTAL
Intervention: VASP-guided clopidogrel maintenance doses
Number of subjects: 306
Study 21538380 — intervention group
Group type: COMPARATOR
Intervention: Control group with fixed clopidogrel doses
Number of subjects: 306
Study 21538380 — intervention group
Group type: EXPERIMENTAL
Intervention: VASP-guided group
Number of subjects: 306
Study 21538380 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 306
Study 19183847 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum of critical health literacy
Number of subjects: 45
Study 19183847 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained students)
Number of subjects: 45
Study 16543930 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 45
Study 16543930 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 45
Study 16543930 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 45
Study 15118975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa 4 g/day
Number of subjects: 304
Study 15118975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 11509936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 136
Study 11509936 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 136
Study 11301563 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-188494 (10 mg daily for 2 weeks)
Number of subjects: 45
Study 11301563 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-188494 (25 mg daily for 4 weeks)
Number of subjects: 45
Study 11301563 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-188494 (50 mg daily for 4 weeks)
Number of subjects: 45
Study 11301563 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-188494 (100 mg daily for 4 weeks)
Number of subjects: 45
Study 11301563 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-188494 (200 mg daily for 4 weeks)
Number of subjects: 45
Study 11301563 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-188494 (all doses)
Number of subjects: 45
Study 11301563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7798537 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 8
Study 7798537 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 8
Study 7798537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2848876 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 ppm F and 1% pyrophosphate
Number of subjects: 15
Study 2848876 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 ppm F
Number of subjects: 15
Study 2848876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no active agents)
Number of subjects: 15
Study 31237335 — intervention group
Group type: EXPERIMENTAL
Intervention: LND diet with 0.9% Ca
Number of subjects: 720
Study 31237335 — intervention group
Group type: EXPERIMENTAL
Intervention: LND diet with 0.7% or more Ca
Number of subjects: 720
Study 31237335 — intervention group
Group type: COMPARATOR
Intervention: LND diet with 0.5% Ca
Number of subjects: 720
Study 28287751 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction after stress
Number of subjects: 0
Study 28287751 — intervention group
Group type: COMPARATOR
Intervention: Rest after stress
Number of subjects: 0
Study 28287751 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction after TSST
Number of subjects: 0
Study 28287751 — intervention group
Group type: COMPARATOR
Intervention: Rest after TSST
Number of subjects: 0
Study 25265096 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal plasma
Number of subjects: 100
Study 25265096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 100
Study 24180316 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led lifestyle intervention program including eleven small group sessions, two diabetes prevention education sessions, a participant handbook, a participant workbook, and a health education booklet.
Number of subjects: 60
Study 24180316 — intervention group
Group type: COMPARATOR
Intervention: Health education booklet containing information on symptoms, complications, and risk factors of T2DM.
Number of subjects: 60
Study 20460232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk (5 microg vitamin D3)
Number of subjects: 73
Study 20460232 — intervention group
Group type: COMPARATOR
Intervention: Control milk (unfortified)
Number of subjects: 73
Study 18402683 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the lifestyle intervention trial
Number of subjects: 100
Study 18402683 — intervention group
Group type: COMPARATOR
Intervention: Non-participants in the lifestyle intervention trial
Number of subjects: 100
Study 16537882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural fibrinolytic therapy
Number of subjects: 575
Study 16537882 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 575
Study 14696661 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable hydroxyapatite (HA group)
Number of subjects: 83